Cann Group Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Cann Group te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Pharmaceuticals winstgroei	49.3%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%

Sep 24

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Nov 03

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

Feb 23

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Nov 25

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Nov 25

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Cann Group onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

ASX:CAN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	18	-51	-18	-15	N/A
3/31/2024	20	-40	-19	-16	N/A
12/31/2023	21	-29	-20	-17	N/A
9/30/2023	21	-32	-23	-20	N/A
6/30/2023	21	-34	-26	-23	N/A
3/31/2023	18	-35	-30	-25	N/A
12/31/2022	14	-37	-35	-28	N/A
9/30/2022	13	-32	-50	-24	N/A
6/30/2022	11	-26	-66	-20	N/A
3/31/2022	10	-25	-68	-17	N/A
12/31/2021	9	-24	-70	-14	N/A
9/30/2021	9	-25	-54	-18	N/A
6/30/2021	9	-25	-37	-21	N/A
3/31/2021	7	-22	-32	-22	N/A
12/31/2020	6	-18	-26	-22	N/A
9/30/2020	4	-17	-39	-20	N/A
6/30/2020	2	-17	-52	-18	N/A
3/31/2020	2	-16	-58	-14	N/A
12/31/2019	3	-14	-64	-10	N/A
9/30/2019	3	-13	-48	-9	N/A
6/30/2019	3	-11	-33	-7	N/A
3/31/2019	2	-10	-23	-7	N/A
12/31/2018	1	-8	-13	-7	N/A
9/30/2018	1	-6	-11	-5	N/A
6/30/2018	1	-5	-9	-4	N/A
3/31/2018	0	-4	N/A	-3	N/A
12/31/2017	0	-3	N/A	-2	N/A
9/30/2017	0	-3	N/A	-2	N/A
6/30/2017	0	-3	N/A	-2	N/A
6/30/2016	0	-1	N/A	-1	N/A
6/30/2015	0	-4	N/A	-1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van CAN boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van CAN naar verwachting sneller zal groeien dan de markt Australian

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van CAN naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van CAN naar verwachting sneller zal groeien dan de markt Australian.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van CAN naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CAN naar verwachting over 3 jaar hoog zal zijn

Cann Group Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023

Cann Group Limited Revises Revenue Guidance for the Year 2021

Price target lowered to AU$1.12

Analysts update estimates

Recent updates

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.

Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%

Cann Group Limited, Annual General Meeting, Oct 28, 2024

Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)

Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Cann Group Limited Appoints Jenni Pilcher as Managing Director

Less than half of directors are independent

Cann Group Limited's (ASX:CAN) Low P/S No Reason For Excitement

New major risk - Financial position

Cann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory Affairs

A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share Price

Cann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.

Cann Group Limited, Annual General Meeting, Oct 26, 2023

Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)

New minor risk - Financial data availability

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.

Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023

Cann Group (ASX:CAN) Is Making Moderate Use Of Debt

First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)

Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical Trail

Cann Group Limited Announces Chief Executive Officer Changes

Cann Group Limited Announces Final Clinical Trial Participant Completes Study

Less than half of directors are independent

Cann Group Limited Appoints Julian John Chick as Director

Cann Group Limited Announces Resignation of Peter Crock as CEO

Cann Group Limited Meets its Enrolment Target for Phase III Clinical Trial of Low-Dose Satipharm CBD Capsules for Short-Term Sleep Disturbance

Cann Group Limited Announces Executive Changes

Cann Group Limited Appoints Robert Barnes & Julian Chick to the Board

Cann Group Limited Announces Resignation of John Sharman as Director

Cann Group Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)

Cann Group Limited Announce Therapeutic Goods Administration Grants Cann GMP License to Manufacture Therapeutic Goods

Cann Group Limited Receives Second Payment from Victorian Government's Regional Jobs Fund Program

Less than half of directors are independent

Office of Drug Control Grants Permit for Manufacture of Medicinal Cannabis Products to Cann Group Limited

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Cann Group Limited Announces Resignation of Mr. Geoffrey Pearce as Non-Executive Director

Cann Group Limited Announces Cann to Begin Recruitment for CBD Phase 3 Clinical Trial

Rua Bioscience Limited (NZSE:RUA) agreed to acquire 8.36% stake in Zalm Therapeutics Ltd from Cann Group Limited (ASX:CAN) for NZD 10 million.

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Chief Financial Officer Greg Bullock has left the company

Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)

Cann Group Limited Revises Revenue Guidance for the Year 2021

Cann Group Limited (ASX:CAN) completed the acquisition of Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT)

Cann Group Limited, Olivia Newton-John Cancer Research Institute and Austin Health Partnered in A Clinical Tria to Assess Medicinal Cannabis for Symptom Management in People with Advanced Cancer

Cann Group Limited (ASX:CAN) entered into a definitive sale agreement to acquire Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT).

First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

Cann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million.

New 90-day high: AU$0.78

Australis Capital Inc. and Cann Group Limited Sign Agreement

Price target lowered to AU$1.12

Cann Group Limited Receives Initial 19,000 Unit Order for Europe

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Analysts update estimates

New 90-day high: AU$0.51

Deputy Chairman recently bought AU$55k worth of stock

An unknown buyers acquired 11.84% stake in Cann Group Limited (ASX:CAN) from Aurora Cannabis Inc. (TSX:ACB).

New 90-day low: AU$0.38

Cann Group Limited(ASX:CAN) dropped from S&P Global BMI Index

Deputy Chairman recently bought AU$79k worth of stock

Full year earnings released - AU$0.12 loss per share

New 90-day low - AU$0.45

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 25.9 million.

New 90-day low - AU$0.46

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 14.3 million.

New 90-day low - AU$0.72

Cann Group Limited(ASX:CAN) dropped from S&P/ASX All Ordinaries Index

Winst- en omzetgroeiprognoses